Article

Alcon adds to AcrySof family of presbyopia-correcting IOLs

The AcrySof IQ ReSTOR +2.5-D IOL offers sharp distance vision with an additional range of vision beyond a standard monofocal lens.

Milan, Italy-Alcon announced the launch of the AcrySof IQ ReSTOR +2.5-D multifocal IOL during the 2012 meeting of the European Society of Cataract and Refractive Surgeons.

The new lens is built on the proven AcrySof IQ IOL platform and is designed to deliver sharp distance vision for patients undergoing cataract surgery who have distant-dominant visual needs, the company said.

“With the addition of the AcrySof IQ ReSTOR +2.5 IOL, Alcon continues to bring surgeons the broadest portfolio of presbyopia-correcting IOLs,” said Stuart Raetzman, head of Global Commercial Strategy, Alcon. “The optic design of the new lens is made to optimize visual performance at intermediate and far distances.”

The IOL received the CE Mark earlier this year, but it is not yet available in the United States. The lens is also available on the Toric IOL platform for patients with cataract and pre-existing astigmatism. The company expects to make both lenses available in other markets as approvals are received.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.